Back to results
RecruitingPhase 2Phase 3

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

NCT07079735

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

NYP-Weill Cornell

New York, New York, United States

+1 additional location

Contact

Afsana Rahman, MD

2123054600ar3262@cumc.columbia.edu
View on ClinicalTrials.gov
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant — TrialFind